FIG 6.

Isoginkgetin induces apoptosis in human MM cell lines in vitro and displays a higher rate of cell death than bortezomib. (A) Cell viability assays and corresponding IC50 values in multiple myeloma cell lines treated with various doses of isoginkgetin or bortezomib (BTZ) for 72 h (n = 3; values graphed as a percentage compared to the values for untreated control samples). (B) Western blot analysis of PARP-1 and tubulin expression in MM cell lines treated with 30 μM isoginkgetin for 8 or 24 h. (C) Analysis of cell viability in MM cell lines treated with 30 μM isoginkgetin or 20 nM bortezomib for 24 h (n = 3) (values graphed as a percentage compared to the values for untreated control samples).